| |
Newsroom /
Health and Fitness
/
Health and Fitness
/
Post-Traumatic Stress Disorder (PTSD) Therapeutics
Post-Traumatic Stress Disorder (PTSD) Therapeutics
PTSD Therapeutics Market is Forecast to Show Slow Growth until 2017, The report identifies the key trends shaping and driving the global PTSD therapeutics market.
Hyderabad,
AP,
India
(prbd.net)
22/06/2011
GlobalData estimates that the global Post - traumatic Stress Disorder (PTSD) therapeutics market was
valued at $2.2 billion in 2010, and it is expected to grow at a Compound Annual Growth Rate (CAGR) of
4.2% over the next seven years, to reach $2.9 billion by 2017. This slow growth is primarily attributed to
low disease awareness and usage of generic drugs. The current competitive landscape consists of
branded, generic and off - label drugs.
GlobalData’s research indicates that the PTSD pipeline is weak with 16 molecules in various phases of
clinical development. The first - in - class molecules seem to have distinct advantages over the current
products in terms of better disease management. The unmet need of the PTSD market is low and
treatment relies on older therapies and drugs. The market needs therapies offering better results in terms of safety and efficacy.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Post-Traumatic-Stress-Disorder-%28PTSD%29-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
The existing market landscape remains competitive, because treatment of PTSD relies on established, older therapies such as Selective Serotonin Reuptake Inhibitors (SSRIs). The market scenario is expected to change after the launch of new therapies such as Alpha and Beta Adrenergic Receptor antagonists, N - methyl D - aspartate (NMDA) receptor modulators, Corticotropin Releasing Factor (CRF1) inhibitors, Progesterone receptor antagonist, V1 Receptor antagonists, and mGluR7 NAM inhibitor.
GlobalData’s analysis shows that the PTSD therapeutics pipeline is weak, with 16 molecules in various
phases of clinical development, including 12 first - in - class molecules. These first - in - class molecules
however, are mostly in the early stage of clinical development, and their impact on the market is not
expected to be seen during the forecast period to 2017. The Phase III molecules in the pipeline are both
generics and are not expected to show any impact on the PTSD market. As a result, the pipeline for the
PTSD therapeutics market is expected to have its impact on the market beyond 2017.
GlobalData, the industry analysis specialist, has released its new report, “Post-Traumatic Stress
Disorder (PTSD) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is
an essential source of information and analysis on the global PTSD therapeutics market. The report
identifies the key trends shaping and driving the global PTSD therapeutics market. The report also
provides insights on the prevalent competitive landscape and the emerging players expected to
significantly alter the market positioning of the current market leaders. Most importantly, the report
provides valuable insights on the pipeline products within the global PTSD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Post-Traumatic-Stress-Disorder-%28PTSD%29-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report
Visit our report store: http://www.globaldata.com/reportstore
For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782
About
GlobalData is a global market intelligence services company providing information research and analysis products and services.
|